Y. İLHAN Et Al. , "Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer," International Journal of Gynecological Cancer , vol.32, pp.502-507, 2022
İLHAN, Y. Et Al. 2022. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. International Journal of Gynecological Cancer , vol.32 , 502-507.
İLHAN, Y., TATLI, A. M., Teker, F., Onder, A. H., Kose, F., Geredeli, C., ... Karaagac, M.(2022). Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. International Journal of Gynecological Cancer , vol.32, 502-507.
İLHAN, YUSUF Et Al. "Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer," International Journal of Gynecological Cancer , vol.32, 502-507, 2022
İLHAN, YUSUF Et Al. "Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer." International Journal of Gynecological Cancer , vol.32, pp.502-507, 2022
İLHAN, Y. Et Al. (2022) . "Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer." International Journal of Gynecological Cancer , vol.32, pp.502-507.
@article{article, author={YUSUF İLHAN Et Al. }, title={Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer}, journal={International Journal of Gynecological Cancer}, year=2022, pages={502-507} }